maiden result combin compani import season
appear better peer flat underli sale small growth bayer
legaci small declin monsanto legaci report growth flatten
basf servic contract howev bayer remain confid
underli guidanc like continu reflect tough us
market growth driven latam combin
group look leverag bayer chemic strong monsanto seed
see easier comp row expect us shift corn soybean
plant remain posit profit final resolut glyphos
litig still seem far away four trial possibl
johnson trial appeal verdict expect howev hardeman
appeal could year away bayer point possibl differ
jurisdict outsid california potenti yield differ verdict
despit on-going litig underli demand remain strong
pharma remain domin xarelto eylea china drive em
strong growth darolutmid remain largest near-term opportun
manag talk differenti safeti assum
potenti expect slow ramp payer look step therapi approach
given avail gener zytiga mirror erleada perform
catalyst risk pilliod trial verdict expect mid-may xarelto
progress dispos currenta copperton possibl dr scholl
anim health expect newsflow
valuat bayer trade pe discount global
crop major eu pharma peer trade discount
pharmavalu equiti npv vs peer discount make minim
chang number
valuat metric
price-to-earnings rel local market
number share
price month
price rel chart measur perform
deutsch bors dax close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
bayer ag german manag hold compani core
compet field life scienc intens group
segment report pharmaceut consum anim
crop scienc
assum higher growth rate pharma rais potenti
penetr xarelto compass indic
assum pharma success show higher
agrochem growth boost potenti higher crop price
assum requir glyphos litig reserv
use central case
assum success lower xarelto growth reflect
poor compass indic uptak continu share gain
competitor assum essenti agrochem growth
continu glyphos litig risk inabl grow
monsanto busi face glyphos litig fear
includ impact litig risk
price rel chart measur perform deutsch
bors dax close
spot exchang rate
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
figur credit suiss division estim compar compani guidanc
ebitda special item
limit impact
ebitda special item
ebitda special item
expect shift
moder
growth
strong growth
latin
ebitda special item
impact
portfolio
chang
chang /-
sale
/-
sale
stabl
increas
sensitivity/ fx benefit sale
sensitivity/ fx benefit ebitda
cap ppe/intang eurm
sale
restructur /special item ebitda level
anim health updat
week may
st loiu
fusion cancer
dr scholl
annouc
currenta
advanc
dkd
bayer premium/ discount eu
bayer premium/ discount global
bayer premium/ discount global
charl martineau univers toronto chang forecast
figur old new forecast made minim chang earn
strong start year sale yoy track make guidanc almost
doubl
guidanc confirm
pharma fda inspect conduct march complet profit growth
consum new fit win initi start deliv fy guidanc
effici programm synergi realiz track
portfolio measur divest track time currenta advanc
expect news one divest dr scholl copperton quarter
crop scienc sale half growth relat basf servic agreement ebitda
special item
growth driven latin america north america
growth across herbicid insecticid off-set cotton trait
track xtend technolog across soy cotton climat fieldview
track deliv synergi target synergi
updat glyphos litig convinc safeti profil glyphos
april plaintiff jan file first brief appeal johnson trial
pilliod trial result expect may trial schedul
pharma sale yoy ebitda special despit neg fx
impact
xarelto driven sale china japan eylea volume increas
region grew
xalerto low dd rang elyea growth rang
darolutamid submit us europ japan
full global right vitrakvi secur
consum sale ebitda special item
asia/pacif latin america posit growth
intens competit north america suppli disrupt emea
win program deliv first posit result
sale ebitda posit impact
fx posit impact
ep despit increas share count increas interest expens
due debt financ
flow despit signific work capit crop
debt increas due oper leas report right
use asset expect end base current fx rate debt
usd everi decreas increas usd impact debt
confirm guidanc sale ebitda margin
ep base cc includ anim health coppertone/dr
scholl currenta
confirm guidanc take account anim health coppertone/dr
scholl currenta divest
deliv oper target
integr crop advanc number platform
execut effici program realiz synergi
continu vigor defens glyphos litig
strengthen pipelin intern extern
drive improv consum health plan growth expand ebitda
margin
question answer
 soybean competit pressur us
pretti signific declin half due phase due chang ifr
second part declin due us lower acreag discount relat
germin issu due wet season relat competit price
 issu raw materi price
pressur start last year china go green initi compens
 sale anim health vs spin
analys best rout exit due attract busi earn
profil high level interest middl carv anim health
see potenti sale end year
updat materi item includ eu launch vitrakvi
darolutamid file expect us launch
data primari complet august voyag pad programm primari
complet vericiguat hf-ref patient
 mani acr sell intacta much expect sell
sold acr primarili latam work acr
 mani acr sell xtend much expect sell
sold work acr
 unfavour mix corn us
see corn rout worm pressur farm around fring corn rout worm pressur
weaker corn rout worm season farmer fring trade
judg ask settlement discuss two verdict
bayer vigor defend wait addit four trial year
way earli got level comfort base yet
 expect feedback fda inspect
file respons fda audit report wait offici fda answer
interest high broad
 monsanto ebitda contribut
report legaci monsanto look legaci monsanto sale ebitda
slightli relat soybean ifr phase
 contribut synergi quarter
break quarter track less cost synergi achiev
end last year expect year also expect start see sale
synergi latam year
 herbicid glyphos
eu latam significantli price volum north america due
gener channel season delay north america consum side
roundup good demand impact glyphos case
 growth crop get guidanc crop year
believ valid number look pro-forma number flat
shift corn due weather situat mid-west delay entir
plant season expect declin soybean acreag overal hemispher expect
modest growth expect growth latam apac confirm growth
guidanc year
 adalat avelox strong stock number
china demand effect geographi neglig
 support strong eylea perform
pleas result seen continu market expans cautiou
price volum mix rest year that bayer retain growth rate
 done drive growth china em
strive sale china headwind valu base
price model govern launch want get nation formulari
reimburs list quickli done xarelto doubl sale
quarter need keep innov look establish product long
 pro-forma growth corn soybean
corn flat due declin latam relat earli soybean harvest
allow second crop plant earlier off-set increas emea
america flat relat weather situat delay plan
corn soybean
 big pharma busi xarelto china
xarelto saw growth base total china
 veristiguat data
hf-pef hf-ref victora earli next year jan
 moder growth ag expect strong growth latam
confid
seen robust growth latam strong posit brazil expect increas soybean
acreag brazil also expect increas soybean cotton argentina
normal year cotton signific upsid potenti cotton wash
australia last year
 mani second level decis would give comfort settl
look appeal johnson case end year bayer control
difficult hardman case could take two year continu litig case
unfortun posit give colour
 darolutimid feedback kol
excit data vs prosper spartan daro structur differ
penetr blood brain barrier safer product better
qualiti life data efficaci compar class make packag
current growth pure bayer legaci busi half basf servic
agreement half growth legaci monsanto slightli
lead essenti flat pro-forma perform consensu close
bayer expect year end
 anyth differ next four case could lead posit
outcom bayer
tri two case quit bit commentari continu evolv
best tri case three case california next three
four st louis- differ jurisdict rule set region board
involv develop case
 shift trait relat increas transpar price
bayer climat corpor biggest compani price transpar
anyon els feel good high yield product see trade
price transpar
deep dive ag pipelin august number disrupt approach
show case begin august
 xarelto settlement liabil off-set insur
break-out still discuss insur insur
 strateg option pharma establish product
comment futur strategi
group sale restat exclud covestro
compani mention price
